IVVD — Invivyd, Inc.

Summary of Invivyd Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Revenue Growth: Monoclonal antibody revenues showed continued growth, while COVID vaccine revenues declined.
• PEMGARDA Performance: Year-over-year growth of 22% in Q1 2026 compared to Q1 2025, indicating resilience despite seasonal trends.
• Clinical Spending: Significant clinical expenditures were made to support the DECLARATION trial, impacting overall financial burn.
• Cash Position: Strong cash reserves bolstered by recent funding from long-term investors.

2. Strategic Updates and Business Highlights

• DECLARATION Study: Recruitment for the pivotal DECLARATION study is progressing well, with a recent upsizing that exceeded internal expectations. Monitoring time post-administration has been reduced from 2 hours to 30 minutes, indicating confidence in safety.
• Government Affairs: Increased engagement with policymakers in Washington, D.C., with positive feedback on monoclonal antibody therapies.
• Pipeline Expansion: Introduction of early discovery programs targeting additional vaccine-preventable diseases like mumps, rubella, and Lyme disease.
• Public Education Campaign: Partnership with Lindsay Vonn for the "Antibodies for Anybody" campaign aimed at educating the public on the role of antibodies in immunity.

3. Forward Guidance and Outlook

• Clinical Trials: Anticipation of completing the DECLARATION study soon, with plans to initiate the LIBERTY study to compare monoclonal antibodies with COVID-19 vaccines.
• Market Positioning: Expectation of leveraging existing infrastructure for the commercialization of VYD2311, pending FDA approval.
• Long-term Vision: Aiming to establish monoclonal antibodies as a mainstream option for infectious disease prevention and treatment, enhancing public health outcomes.

4. Bad News, Challenges, or Points of Concern

• Declining Vaccine Utilization: Notable decline in COVID vaccine usage, which may impact overall market dynamics.
• Competitive Pressures: Acknowledgment of another company's abandonment of a major vaccine study due to low demand, highlighting potential market challenges.
• Regulatory Uncertainty: The need for FDA approval remains a critical hurdle, with no guarantees on the outcomes of ongoing studies.

5. Notable Q&A Insights

• Safety Monitoring: Questions raised about the implications of reduced monitoring time post-administration and its potential impact on adoption; management expressed optimism about safety profiles.
• Efficacy Expectations: Discussions on the expected efficacy of VYD2311, with management indicating that even low efficacy could provide symptomatic benefits, but they anticipate much higher efficacy based on their dosing strategy.
• Public Health Strategy: Emphasis on the need for rational use of monoclonal antibodies in response to outbreaks, with a vision for a more data-driven approach to prophylaxis in infectious diseases.

Overall, Invivyd is optimistic about its strategic direction and the potential impact of its monoclonal antibody therapies, despite facing challenges in the broader vaccine market and the need for regulatory approvals.